Draft:Piramal Pharma Solutions

Piramal Pharma Solutions Invests ~$32 Million to Expand its Riverview Michigan Facility for Additional Capacity in Potent and Non-Potent API Development and Manufacturing

Retrieved on: 
Tuesday, December 8, 2020
Draft:Piramal Pharma Solutions, Contract manufacturing organization, Piramal

RIVERVIEW, Michigan, Dec. 8, 2020 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).

Key Points: 
  • RIVERVIEW, Michigan, Dec. 8, 2020 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).
  • The company is investing ~US$32 million in the facility to keep up with expected demand based on current forecasts, including potential new opportunities.
  • Peter DeYoung, CEO, Piramal Pharma Solutions said, "Piramal Pharma Solutions' Riverview facility has a well-earned reputation as the preeminent leader in high potency APIs (HPAPIs), and this expansion is designed to ensure that we retain that position.
  • Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.

Piramal Pharma Solutions Invests ~$32 Million to Expand its Riverview Michigan Facility for Additional Capacity in Potent and Non-Potent API Development and Manufacturing

Retrieved on: 
Tuesday, December 8, 2020
Draft:Piramal Pharma Solutions, Contract manufacturing organization, Piramal

RIVERVIEW, Michigan, Dec. 8, 2020 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).

Key Points: 
  • RIVERVIEW, Michigan, Dec. 8, 2020 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs).
  • The company is investing ~US$32 million in the facility to keep up with expected demand based on current forecasts, including potential new opportunities.
  • Peter DeYoung, CEO, Piramal Pharma Solutions said, "Piramal Pharma Solutions' Riverview facility has a well-earned reputation as the preeminent leader in high potency APIs (HPAPIs), and this expansion is designed to ensure that we retain that position.
  • Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.

Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs

Retrieved on: 
Thursday, August 27, 2020
Contract manufacturing organization, Pharmaceutical industry, Pharma, Piramal, Draft:Piramal Pharma Solutions

The Piramal Pharma Solutions (PPS) team is providing Epirium with an integrated program that encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product.

Key Points: 
  • The Piramal Pharma Solutions (PPS) team is providing Epirium with an integrated program that encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, "This program with Epirium exemplifies the ways we lead the market in delivering integrated services.
  • Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.
  • Piramal Pharma Solutions is a part of PEL's Pharma business that provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.)

Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs

Retrieved on: 
Thursday, August 27, 2020
Contract manufacturing organization, Pharmaceutical industry, Pharma, Piramal, Draft:Piramal Pharma Solutions

The Piramal Pharma Solutions (PPS) team is providing Epirium with an integrated program that encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product.

Key Points: 
  • The Piramal Pharma Solutions (PPS) team is providing Epirium with an integrated program that encompasses formulation development, supply of APIs and intermediates, chemistry development and manufacturing, and solid oral dosage form drug product.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, "This program with Epirium exemplifies the ways we lead the market in delivering integrated services.
  • Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.
  • Piramal Pharma Solutions is a part of PEL's Pharma business that provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.)

United States' Corporate Pharma Reputation in 2019 - Survey Findings from 186 Patient Groups

Retrieved on: 
Tuesday, August 4, 2020
Health, Pharmaceutical sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Draft:Piramal Pharma Solutions, Bundesverband der Pharmazeutischen Industrie

Company analyses: 39 pharma companies analysed for performance at 12 indicators of corporate reputation by US patient groups familiar with the company, and by US patient groups that work or partner with the company.

Key Points: 
  • Company analyses: 39 pharma companies analysed for performance at 12 indicators of corporate reputation by US patient groups familiar with the company, and by US patient groups that work or partner with the company.
  • 48% of 2019's respondent US patient groups stated that the pharmaceutical industry had an Excellent or Good corporate reputation.
  • However, US patient groups only ranked the pharmaceutical industry 3rd in 2019 for corporate reputation out of nine healthcare sectors; the pharmaceutical industry was ranked 1st by patient groups worldwide.
  • US patient-group relationships with pharma, 2019
    Rankings of the 39 pharma companies, 2019 (v. 2018) among US patient groups familiar with the companies
    Rankings of the 23 pharma companies, 2019 (v. 2018) among US patient groups that work with the companies
    Profiles of the 39 companies, 2019 (v. 2018)

Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish

Retrieved on: 
Wednesday, July 29, 2020
Contract manufacturing organization, Pharmaceutical industry, Pharma, Piramal, Draft:Piramal Pharma Solutions

The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt's BDC-1001 for the treatment of patients with HER2-expressed solid tumors.

Key Points: 
  • The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt's BDC-1001 for the treatment of patients with HER2-expressed solid tumors.
  • Nathan Ihle, VP CMC & Quality for Bolt Biotherapeutics added, "Bolt is a leader in ISAC technology, and our partnership with Piramal Pharma Solutions is important to bring our technology to the clinic.
  • Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.
  • Piramal Pharma Solutions is a part of PEL's Pharma business that provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.)

Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish

Retrieved on: 
Wednesday, July 29, 2020
Contract manufacturing organization, Pharmaceutical industry, Pharma, Piramal, Draft:Piramal Pharma Solutions

The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt's BDC-1001 for the treatment of patients with HER2-expressed solid tumors.

Key Points: 
  • The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt's BDC-1001 for the treatment of patients with HER2-expressed solid tumors.
  • Nathan Ihle, VP CMC & Quality for Bolt Biotherapeutics added, "Bolt is a leader in ISAC technology, and our partnership with Piramal Pharma Solutions is important to bring our technology to the clinic.
  • Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle.
  • Piramal Pharma Solutions is a part of PEL's Pharma business that provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.)